TM Editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Image Source: Pixabay

Deals and Financings

KBP Biosciences, a Singapore-China company, sold global rights for its novel late-stage hypertension candidate to Denmark’s Novo Nordisk (NVO) in an agreement worth up to $1.3 billion.

Additionally, Jiangsu Hengrui Medicine out-licensed global rights (ex-China) for its anti-PD-1 antibody to New Jersey’s Elevar Therapeutics in a $1 billion deal.

Meanwhile, Shanghai EpimAb Bio sold the rights to use its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to Barcelona’s Almirall (LBTSF) in a $210 million agreement.

Also, Shanghai Belief BioMed out-licensed China commercialization rights to Takeda China for its lead candidate, an AAV gene therapy for hemophilia B.

SparX Group (SRXXF), a Chicago company with China subsidiaries, announced that its Claudin 18.2 mAb will be part of an off-the-shelf CAR-iNKT cell therapy developed by South Africa’s Arovella.

Company News

WuXi Biologics (WXXWY), a global CRDMO headquartered in Shanghai, launched a bioprocessing platform, WuXiUI, with a 3- to 6-fold increase in productivity and a 60-80% savings in cost.

Trials and Approvals

Beijing CANbridge Pharma reported China’s NMPA accepted for review its NDA for pruritus, a rare disease, in patients who are at least two months old.

Meanwhile, Beijing’s BeiGene (BGNE) reported positive data from a global Phase III trial of its anti-PD-1, tislelizumab, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Suzhou Ascentage Pharma (ASPHF) dosed the first patient in a China Phase III trial of its lead drug, olverembatinib, in patients with acute lymphoblastic leukemia.

Finally, Shanghai Skyline Therapeutics was approved to start China clinical trials of an AAV gene therapy aimed at neovascular age-related macular degeneration.

More By This Author: